Reported 8 months ago
As Eli Lilly competes in the same market as Madrigal Pharmaceuticals, with a bid to introduce tirzepatide for treating type-2 diabetes and obesity, investors are advised to be cautious. The FDA approval of tirzepatide could potentially impact Madrigal's market share for MASH treatment, as Eli Lilly's medicine has shown more effectiveness in reversing fibrosis, a key symptom of the disease. Madrigal investors are advised to hold onto their shares for now, as the competition unfolds and further R&D efforts are required for long-term success.
Source: YAHOO